{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:52:40Z","timestamp":1777578760037,"version":"3.51.4"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL113508"],"award-info":[{"award-number":["R01HL113508"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Pneumothorax has been increasingly observed among patients with coronavirus disease-2019 (COVID-19) pneumonia, specifically in those patients who develop acute respiratory distress syndrome (ARDS). In this study, we sought to determine the incidence and potential risk factors of pneumothorax in critically ill adults with COVID-19.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Method<\/jats:title>\n<jats:p>This retrospective cohort study included adult patients with laboratory-confirmed SARS-CoV-2 infection admitted to one of the adult intensive care units of a tertiary, academic teaching hospital from May 2020 through May 2021.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among 334 COVID-19 cases requiring ICU admission, the incidence of pneumothorax was 10% (33 patients). Patients who experienced pneumothorax more frequently required vasopressor support (28\/33 [84%] vs. 191\/301 [63%] P = 0.04), were more likely to be proned (25\/33 [75%] vs. 111\/301 [36%], P&lt;0.001), and the presence of pneumothorax was associated with prolonged duration of mechanical ventilation; 21 (1\u201397) versus 7 (1\u201379) days, p&lt;0.001 as well as prolonged hospital length of stay (29 [9\u2013133] vs. 15 [1\u201390] days, P&lt;0.001), but mortality was not significantly different between groups. Importantly, when we performed a Cox proportional hazard ratio (HR) model of multivariate parameters, we found that administration of tocilizumab significantly increased the risk of developing pneumothorax (HR = 10.7; CI [3.6\u201332], P&lt;0.001).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Among 334 critically ill patients with COVID-19, the incidence of pneumothorax was 10%. Presence of pneumothorax was associated with prolonged duration of mechanical ventilation and length of hospital stay. Strikingly, receipt of tocilizumab was associated with an increased risk of developing pneumothorax.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0271964","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T17:31:26Z","timestamp":1659720686000},"page":"e0271964","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Incidence and risk factors of COVID-19 associated pneumothorax"],"prefix":"10.1371","volume":"17","author":[{"given":"Muhanad","family":"Taha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morvarid","family":"Elahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Wahby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3327-2585","authenticated-orcid":true,"given":"Lobelia","family":"Samavati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"issue":"5","key":"pone.0271964.ref001","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"X Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"pone.0271964.ref002","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3389\/fpubh.2020.587374","article-title":"Asymptomatic SARS-CoV-2 Carriers: A Systematic Review and Meta-Analysis","volume":"8","author":"G Syangtan","year":"2021","journal-title":"Frontiers in Public Health"},{"issue":"3","key":"pone.0271964.ref003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249038","article-title":"ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida","volume":"16","author":"E Oliveira","year":"2021","journal-title":"PLoS One"},{"issue":"620","key":"pone.0271964.ref004","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1126\/scitranslmed.abj7790","article-title":"Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19","volume":"13","author":"F D\u2019Agnillo","year":"2021","journal-title":"Science Translational Medicine"},{"key":"pone.0271964.ref005","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fcimb.2020.00317","article-title":"ACE2, Much More Than Just a Receptor for SARS-COV-2","volume":"10","author":"L Samavati","year":"2020","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"issue":"7","key":"pone.0271964.ref006","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/jth.14869","article-title":"High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients","volume":"18","author":"JF Llitjos","year":"2020","journal-title":"J Thromb Haemost"},{"key":"pone.0271964.ref007","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106464","article-title":"Pneumothorax in critically ill patients with COVID-19 infection: Incidence, clinical characteristics and outcomes in a case control multicenter study","volume":"184","author":"A Chopra","year":"2021","journal-title":"Respir Med"},{"key":"pone.0271964.ref008","doi-asserted-by":"crossref","first-page":"106552","DOI":"10.1016\/j.rmed.2021.106552","article-title":"Pneumothorax and barotrauma in invasively ventilated patients with COVID-19","volume":"187","author":"A Belletti","year":"2021","journal-title":"Respiratory Medicine"},{"issue":"4","key":"pone.0271964.ref009","first-page":"00385","article-title":"Pneumomediastinum and subcutaneous emphysema in COVID-19: barotrauma or lung frailty?","volume":"6","author":"DHL Lemmers","year":"2020","journal-title":"ERJ Open Research"},{"key":"pone.0271964.ref010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejim.2021.03.018","article-title":"Pneumothorax\/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave","volume":"88","author":"D Palumbo","year":"2021","journal-title":"European Journal of Internal Medicine"},{"issue":"16","key":"pone.0271964.ref011","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia","volume":"384","author":"IO Rosas","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pone.0271964.ref012","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial","volume":"181","author":"C Salvarani","year":"2021","journal-title":"JAMA Internal Medicine"},{"issue":"9617","key":"pone.0271964.ref013","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"JS Smolen","year":"2008","journal-title":"The Lancet"},{"issue":"3","key":"pone.0271964.ref014","article-title":"Tocilizumab for severe COVID-19: a systematic review and meta-analysis","volume":"56","author":"SH Lan","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"24","key":"pone.0271964.ref015","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of Tocilizumab in Patients Hospitalized with Covid-19","volume":"383","author":"JH Stone","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"pone.0271964.ref016","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19","volume":"384","author":"AC Gordon","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"pone.0271964.ref017","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM200005043421801","article-title":"Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome","volume":"342","author":"RG B","year":"2000","journal-title":"N Engl J Med"},{"key":"pone.0271964.ref018","doi-asserted-by":"crossref","unstructured":"Adarsh Bhimraj A, Morgan RL, Hirsch Shumaker A, Lavergne V, Baden L, Chi-Chung Cheng V, et al. Last updated October 18, 2021 and posted online at www.idsociety.org\/COVID19guidelines. Please check website for most updated version of these guidelines. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. [cited 2021 Oct 20]; www.idsociety.org\/COVID19guidelines.","DOI":"10.1093\/cid\/ciaa478"},{"issue":"5","key":"pone.0271964.ref019","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"ME Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"10","key":"pone.0271964.ref020","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"WA Knaus","year":"1985","journal-title":"Crit Care Med"},{"issue":"2","key":"pone.0271964.ref021","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.1148\/radiol.2020202352","article-title":"Increased incidence of barotrauma in patients with COVID-19 on invasive mechanical ventilation","volume":"297","author":"G McGuinness","year":"2020","journal-title":"Radiology"},{"issue":"4","key":"pone.0271964.ref022","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00134-004-2187-7","article-title":"Incidence, risk factors and outcome of barotrauma in mechanically ventilated patients","volume":"30","author":"A Anzueto","year":"2004","journal-title":"Intensive Care Med"},{"issue":"9","key":"pone.0271964.ref023","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1164\/rccm.201703-0548ST","article-title":"An Official American Thoracic Society\/European Society of Intensive Care Medicine\/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome","volume":"195","author":"E Fan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"pone.0271964.ref024","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ccc.2021.05.003","article-title":"Pathophysiology of Acute Respiratory Distress Syndrome and COVID-19 Lung Injury","volume":"37","author":"KE Swenson","year":"2021","journal-title":"Critical Care Clinics"},{"issue":"10229","key":"pone.0271964.ref025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"F Zhou","year":"2020","journal-title":"The Lancet"},{"issue":"10","key":"pone.0271964.ref026","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"DM del Valle","year":"2020","journal-title":"Nature Medicine"},{"issue":"1","key":"pone.0271964.ref027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jmv.26085","article-title":"Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis","volume":"93","author":"J Zhu","year":"2021","journal-title":"J Med Virol"},{"issue":"6","key":"pone.0271964.ref028","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41577-021-00553-8","article-title":"Is IL-6 a key cytokine target for therapy in COVID-19?","volume":"21","author":"SA Jones","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"pone.0271964.ref029","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2146\/ajhp070449","article-title":"Tocilizumab: The first interleukin-6-receptor inhibitor","volume":"65","author":"A. Sebba","year":"2008","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"10","key":"pone.0271964.ref030","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1016\/S2665-9913(20)30277-0","article-title":"Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study","volume":"2","author":"N Biran","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"pone.0271964.ref031","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1093\/cid\/ciaa954","article-title":"Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19","volume":"73","author":"EC Somers","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"8","key":"pone.0271964.ref032","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"G Guaraldi","year":"2020","journal-title":"The Lancet Rheumatology"},{"issue":"1","key":"pone.0271964.ref033","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial","volume":"181","author":"O Hermine","year":"2021","journal-title":"JAMA Internal Medicine"},{"key":"pone.0271964.ref034","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"VC Veiga","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"pone.0271964.ref035","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"pone.0271964.ref036","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia","volume":"384","author":"C Salama","year":"2021","journal-title":"N Engl J Med"},{"issue":"10285","key":"pone.0271964.ref037","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"O Abani","year":"2021","journal-title":"The Lancet"},{"issue":"4","key":"pone.0271964.ref038","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1165\/rcmb.2012-0100TR","article-title":"Human epidermal growth factor receptor signaling in acute lung injury","volume":"47","author":"JH Finigan","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"pone.0271964.ref039","first-page":"1","article-title":"IL-6 ameliorates acute lung injury in influenza virus infection","volume":"7","author":"ML Yang","year":"2017","journal-title":"Scientific Reports"},{"issue":"6","key":"pone.0271964.ref040","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1365-2133.2007.07867.x","article-title":"Interleukin-6 (IL-6) modulates migration and matrix metalloproteinase function in dermal fibroblasts from IL-6KO mice","volume":"156","author":"LR Luckett","year":"2007","journal-title":"Br J Dermatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0271964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T17:32:15Z","timestamp":1659720735000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0271964"}},"subtitle":[],"editor":[{"given":"Andrea","family":"Cortegiani","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0271964","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]}}}